Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 29, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jul. 01, 2012	Apr. 01, 2012	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Restructuring Cost and Reserve [Line Items]
Accelerated depreciation									$ 5	[1]
Total Restructuring charges and certain acquisition-related costs	36	3	(20)	7	80	6	24	25	26		135		154	[2]
Transaction costs(c)													2	[3]
Total costs associated with restructuring, acquisitions and cost-reduction/productivity initiatives									30		168		186
Certain Significant Items
Restructuring Cost and Reserve [Line Items]
Restructuring Charges									(20)
Additional depreciation associated with asset restructuring									8
United States (U.S.)
Restructuring Cost and Reserve [Line Items]
Restructuring Charges													2
Canada and Latin America (CLAR)
Restructuring Cost and Reserve [Line Items]
Restructuring Charges									4		3		2
Asia Pacific (APAC)
Restructuring Cost and Reserve [Line Items]
Restructuring Charges											(1)		(2)
Manufacturing, Research, Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring Charges									(3)		(1)
Cost of Sales
Restructuring Cost and Reserve [Line Items]
Additional depreciation associated with asset restructuring									1		10		6
Research and Development Expense
Restructuring Cost and Reserve [Line Items]
Additional depreciation associated with asset restructuring											9		19
Selling, General and Administrative Expenses
Restructuring Cost and Reserve [Line Items]
Additional depreciation associated with asset restructuring									2		5		4
Certain Significant Items
Restructuring Cost and Reserve [Line Items]
Restructuring Charges											27
Direct Cost
Restructuring Cost and Reserve [Line Items]
Integration costs(a)									21	[4]	26	[4]	30	[4]
Employee termination costs									(23)	[1]	49	[1]	53	[1]
Asset impairment charges									19	[1]	4	[1]	0	[1]
Exit costs									4	[1]	(1)	[1]	1	[1]
Total Restructuring charges and certain acquisition-related costs									26	[3]	78	[3]	84	[3]
Additional depreciation associated with asset restructuring									1	[5]	11	[5]	9	[5]
Implementation costs––allocated(e)									0	[6]	0	[6]	3	[6]
Direct Cost | Europe, Africa, and Middle East (EuAfME)
Restructuring Cost and Reserve [Line Items]
Restructuring Charges									4		51		33
Direct Cost | Manufacturing, Research, Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring Charges													19
Allocated Cost
Restructuring Cost and Reserve [Line Items]
Integration costs(a)									0	[4]	21	[4]	41	[4]
Employee termination costs									0	[1]	19	[1]	20	[1]
Asset impairment charges									0	[1]	10	[1]	7	[1]
Exit costs									0	[1]	7	[1]	0	[1]
Total Restructuring charges and certain acquisition-related costs									0		57		70
Additional depreciation associated with asset restructuring									2	[5]	13	[5]	20	[5]
Implementation costs––allocated(e)									1	[6]	9	[6]	0	[6]
Manufacturing Facility | Direct Cost
Restructuring Cost and Reserve [Line Items]
Asset impairment charges									17	[1]
Facility Closing | Direct Cost
Restructuring Cost and Reserve [Line Items]
Employee termination costs									$ 2	[1]

[1] The restructuring charges (benefits) for the year ended December 31, 2013 are primarily related to the following:•When we were a business unit of Pfizer, we announced a restructuring plan related to our operations in Europe. In connection with these actions, we recorded a pre-tax charge of $27 million to recognize employee termination costs. As a result of becoming an independent public company (no longer being a majority-owned subsidiary of Pfizer) and related economic consideration, we revisited this restructuring action and decided to no longer implement this restructuring plan. As such, we reversed the existing reserve of $27 million in the second quarter of 2013. •We recorded asset impairment charges related to one of our manufacturing facilities of $17 million.•We recorded restructuring charges related to the exiting of certain leased manufacturing and research facilities and recorded employee termination expenses of $2 million, exit costs of $4 million, and accelerated depreciation of $5 million.The direct restructuring charges (benefits) are associated with the following: •For the year ended December 31, 2013––EuAfME ($4 million), CLAR ($4 million) and manufacturing/research/corporate ($3 million income). •For the year ended December 31, 2012—EuAfME ($51 million), CLAR ($3 million), APAC ($1 million income) and manufacturing/research/corporate ($1 million income). •For the year ended December 31, 2011––U.S. ($2 million), EuAfME ($33 million), CLAR ($2 million), APAC ($2 million income) and manufacturing/research/corporate ($19 million).

[2] Includes revenue and expenses from acquisitions from the acquisition date, see Note 3. Basis of Presentation and Note 5. Acquisitions, Divestitures and Certain Investments.

[3] Additional depreciation associated with asset restructuring represents the impact of changes in the estimated lives of assets involved in restructuring actions. In 2013, included in Cost of sales ($1 million) and Selling, general and administrative expenses ($2 million). For 2012, included in Cost of sales ($10 million), Selling, general and administrative expenses ($5 million) and Research and development expenses ($9 million). For 2011, included in Cost of sales ($6 million), Selling, general and administrative expenses ($4 million) and Research and development expenses ($19 million).

[4] Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes, as well as product transfer costs.

[5] Implementation costs—allocated represent external, incremental costs directly related to implementing cost reduction/productivity initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services. Included in Selling, general and administrative expenses.

[6] {F|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOmU0ODZiN2M4NjFhMjQ2MjM4ZjJhMDY0MWI2ZGMxZjU0fFRleHRTZWxlY3Rpb246OTFDRUYwQUY3MDdFRkRCQjc4MURDMzhBQjRGQTU4NzMM}